Targacept has a diverse clinical pipeline built on a unique class of therapeutic targets.
Targacept Inc.
100 North Main Street, Suite 1510
Winston-Salem, NC 27101
Therapeutic Focus:
Nervous system diseases and disorders
Therapeutic Targets:
Neuronal nicotinic receptors (NNRs)
Product Candidates:
TC-5619, negative symptoms and cognitive dysfunction in schizophrenia
TC-5214, overactive bladder
TC-1734, mild to moderate Alzheimer's disease
TC-6987, TBD
AZD1446, TBD
Strategic Alliances:
Global collaboration and license agreement with AstraZeneca AB for AZD1446
Number of Employees:
~40
Date Established:
March 1997
IPO Completed:
April 2006
NASDAQ Ticker Symbol:
TRGT
